Oral Vaccines: How They Work to Create Immunity

Oral vaccines work by introducing a weakened pathogen or a piece of one directly into the gut, where the body’s largest collection of immune tissue recognizes it and mounts a defense. Unlike injected vaccines, which primarily trigger antibodies circulating in the blood, oral vaccines activate the mucosal immune system, producing a specialized antibody called secretory IgA that patrols the very surfaces where many infections begin. This dual activation of both local and body-wide immunity is what makes oral vaccines uniquely suited to diseases that enter through the mouth or nose, though getting a vaccine safely past stomach acid and digestive enzymes is no small engineering feat.

Why the Gut Is an Immune Powerhouse

Your gastrointestinal tract is not just a digestive tube. It contains more immune cells than any other organ system, organized into clusters of lymphoid tissue scattered along the intestinal lining. The most important of these clusters are Peyer’s patches, dome-shaped structures in the small intestine that serve as surveillance stations. Sitting on top of each Peyer’s patch are specialized cells called M cells, whose entire job is to grab material from the intestinal space and shuttle it down to immune cells waiting underneath. M cells do not digest what they find; they pass antigens through intact so the immune system can inspect them and decide whether to react.

Once an antigen reaches the immune cells below an M cell, a cascade begins. Dendritic cells present fragments of the antigen to T cells, which coordinate the broader response, including telling B cells to start producing antibodies. The antibody class that dominates this response is secretory IgA (SIgA). Unlike the IgG antibodies that circulate in blood after an injection, SIgA is secreted directly onto mucosal surfaces: the lining of the gut, the respiratory tract, and even the urogenital tract. SIgA works by trapping pathogens in mucus, blocking them from latching onto the cells they need to infect, and even neutralizing toxins before they cause damage.

This process, sometimes called immune exclusion, is remarkably efficient. SIgA can block a pathogen’s access to the gut lining, entrap it in mucus, and let normal gut movement sweep it out of the body entirely.¹ Critically, the mucosal immune response does not stay local. Immune cells activated in the gut can migrate to other mucosal sites, so an oral vaccine can stimulate protective IgA not only in the intestines but also in the respiratory tract and elsewhere.² This cross-talk between mucosal sites is one reason researchers have explored oral vaccines even for respiratory pathogens like SARS-CoV-2.

The M Cell Gateway

M cells are the linchpin of oral vaccine design. If a vaccine antigen cannot reach M cells, it is unlikely to trigger a meaningful immune response in the gut. These cells are specialized for sampling: their surface is folded into fewer of the finger-like projections that normal intestinal cells use for nutrient absorption, creating a thinner barrier that antigens can cross more easily. Underneath the M cell sits a pocket rich in immune cells, ready to process whatever the M cell hands down.

Pathogens have evolved to exploit this gateway, using M cells as a portal to invade the body. Vaccine designers try to turn that vulnerability into an advantage. By targeting molecules specific to M cells, researchers can steer vaccine antigens toward the cells most likely to deliver them to the immune system.³ The receptors on M cells and the exact mechanism by which they pick up antigens are still not fully mapped, which remains one of the open challenges in oral vaccine development.⁴

Getting Past Stomach Acid and Digestive Enzymes

The biggest obstacle to any oral vaccine is the very system it must pass through. Your stomach produces hydrochloric acid at a pH around 1.5 to 2, along with the enzyme pepsin, both designed to break down proteins. The small intestine then adds more enzymes like trypsin to continue digestion. A protein antigen swallowed without protection will be shredded long before it reaches the Peyer’s patches where it needs to arrive intact.

Live attenuated vaccines, like the oral polio and rotavirus vaccines, sidestep part of this problem by using whole viruses that can survive transit and actually replicate in the gut, producing enough antigen on-site to trigger immunity. But non-living vaccines, or subunit vaccines that consist of just a piece of a pathogen, need physical protection. One approach is microencapsulation: wrapping the antigen in tiny polymer shells that resist stomach acid and dissolve only when they reach the more neutral pH of the small intestine. Early work showed that coating these particles with enteric polymers could protect a significant fraction of the antigen from pepsin at stomach-level acidity.⁵

More recent designs use nanoparticles coated with natural polymers like alginate and chitosan. In lab tests simulating the gut environment, alginate-coated calcium phosphate nanoparticles released only about five to seven percent of their cargo in simulated stomach fluid, keeping the rest intact until they reached a more intestine-like pH.⁶ Another strategy uses bacterial protease inhibitors that, when given alongside the antigen, block digestive enzymes and extend the antigen’s survival time at the immune induction sites in the gut.⁷

The Vaccines You Already Know

The most widely used oral vaccines target diseases that infect through the gut: polio, rotavirus, and cholera. Each illustrates a different facet of how oral immunization works in practice.

The oral polio vaccine (OPV), developed by Albert Sabin, uses live attenuated poliovirus strains that replicate in the intestine. This replication mimics a natural infection closely enough to stimulate strong mucosal IgA as well as blood-borne antibodies, and it confers intestinal immunity that injected vaccines do not match well. The vaccine is given as a few drops on the tongue, which made it the backbone of global polio eradication campaigns. A randomized trial comparing different polio vaccine regimens found that a single dose of monovalent OPV type 1 triggered immune responses in about 79% of recipients, compared with 67% for the bivalent oral version.⁸

Rotavirus vaccines, licensed in 2006 as both a pentavalent and a monovalent formulation, are also live attenuated and given orally. Large clinical trials in Western countries and Latin America demonstrated strong safety and efficacy profiles.⁹ These vaccines work on the same principle as OPV: the weakened virus replicates in the gut, triggering both mucosal and systemic immunity.

Oral cholera vaccines take a different approach. Most currently used formulations are killed whole-cell vaccines, meaning the bacteria are dead and cannot replicate. They rely on sheer antigen volume and the addition of a cholera toxin B subunit to stimulate the immune system. A large phase III trial in Kolkata, India, showed that about 56% of recipients developed a strong antibody rise within two weeks of the second dose.¹⁰ A follow-up trial found that a booster given five years later still induced seroconversion in about two-thirds of adults and roughly 80% of children.¹¹

The Reversion Problem With Live Oral Polio Vaccine

The very feature that makes OPV effective, its ability to replicate in the gut, also carries a risk. The Sabin vaccine strains are genetically unstable, and as they multiply in the intestines, mutations can accumulate that restore the virus’s ability to cause disease. This reversion can begin within days to weeks of vaccination.¹² In rare cases, these reverted viruses spread through communities with low vaccination coverage and cause outbreaks of circulating vaccine-derived poliovirus that are clinically indistinguishable from wild poliovirus disease.¹³

This is not a theoretical concern. The reversion pathway involves specific gatekeeper mutations, and the estimated time from a vaccine dose to the earliest detection of a circulating vaccine-derived strain averages about 210 days for type 2 and about 300 days for type 1.¹² This dilemma has pushed the global health community toward replacing OPV with injected inactivated polio vaccine (IPV) in routine immunization, while a newer, more genetically stable version of OPV (nOPV2) has been developed specifically to reduce the reversion risk. The tension between mucosal immunity and genetic stability remains one of the defining challenges of oral vaccine design.

Why Oral Vaccines Work Less Well in Some Populations

One of the most frustrating puzzles in global health is that oral vaccines consistently perform worse in low-income countries than in high-income ones. Rotavirus vaccine efficacy, for example, drops substantially in parts of South Asia and sub-Saharan Africa compared to the results seen in Western trials. Several factors converge to explain this gap.

The most studied explanation is environmental enteric dysfunction (EED), a condition of chronic gut inflammation driven by malnutrition and repeated infections. EED damages the intestinal lining, flattens the villi that absorb nutrients, and fundamentally changes the immune environment of the gut. In children with EED, researchers have found an expansion of a type of regulatory T cell in the small intestine that actively suppresses the local immune response oral vaccines depend on, while leaving systemic immunity intact.¹⁴ The PROVIDE study confirmed that children with biomarkers of EED at the time of vaccination had lower responses to both oral rotavirus and oral polio vaccines, while their responses to injected vaccines for tetanus, pertussis, and measles were unaffected.¹⁵ This selective failure is a strong clue that the problem lies in the gut environment itself, not in the child’s immune system overall.

Maternal antibodies also interfere. Mothers in regions with high disease burden tend to have high antibody levels, which they pass to their infants both across the placenta and through breast milk. Observational studies in low- and middle-income countries have shown an inverse relationship between maternal antibody titers and infant responses to rotavirus vaccination.¹⁶ Breast milk IgA, in particular, can neutralize the live vaccine virus in the infant’s gut before it has a chance to replicate and provoke immunity.¹⁷ Some studies have tested whether withholding breastfeeding around the time of vaccination improves immune response, but the results have been inconsistent and the strategy raises obvious practical and ethical concerns.¹⁸

The gut microbiome adds another layer. A systematic review of studies on intestinal microbiota and oral vaccine responses found that the mix of bacteria in an infant’s gut at the time of vaccination is associated with whether the vaccine takes, though the direction of the association varies by population. In some cohorts, higher diversity correlated with better responses; in others, specific bacterial groups like Streptococcus bovis or Faecalibacterium prausnitzii were linked to stronger immunity.¹⁹ However, at least one study in south India found no consistent microbiome differences between rotavirus vaccine responders and non-responders, though co-administration of oral polio vaccine did appear to interfere with the rotavirus vaccine’s first dose.²⁰ The microbiome story, in short, is far from settled.

Logistical Advantages in the Field

Beyond immunology, oral vaccines have practical advantages that matter enormously for mass campaigns. They require no needles, no trained injection personnel, and no sharps disposal. A volunteer can administer drops or a drinkable solution with minimal training, which scales far better in remote areas. Oral vaccines have historically been the go-to for campaigns in places with limited health infrastructure, and this partly explains why they have been used almost exclusively against diseases that enter through mucosal surfaces.²¹

Cold chain requirements, the need to keep vaccines refrigerated from factory to arm, are a constant logistical headache for immunization programs in tropical countries. Oral polio vaccine has shown surprising resilience outside the cold chain. During a national immunization campaign in Mali, vaccinators transported OPV without ice packs in ambient temperatures reaching 40°C, and none of the vaccine vials lost their potency.²² A similar study during a campaign in Chad pushed conditions further, with vials exposed to temperatures above 47°C and kept outside the standard 2–8°C range for nearly 87 hours. Post-campaign testing confirmed the vaccine was still potent.²³ This kind of heat stability is a major asset when your supply chain involves motorbikes on unpaved roads and no electricity at the final destination.

Can Oral Vaccines Protect Against Non-Gut Pathogens?

Most licensed oral vaccines target infections of the gut. But the cross-talk between mucosal sites raises an intriguing possibility: could you swallow a vaccine and get protection in your lungs or throat? The immune system does share cells between mucosal surfaces, and immune responses initiated at one mucosal site can influence activity at other mucosal surfaces.²⁴ This is why several groups have pursued oral COVID-19 vaccines: SARS-CoV-2 enters through the nasal mucosa, and stimulating secretory IgA at mucosal surfaces could theoretically block the virus at the front door rather than fighting it once it is already inside.

Research on sublingual delivery, where a vaccine is placed under the tongue, has documented the ability to induce both systemic and mucosal immune responses against a variety of antigens, including proteins and live viruses.²⁵ The sublingual route is attractive because it partly bypasses stomach acid, and the tissue under the tongue is rich in antigen-presenting cells. Still, this approach remains largely experimental for vaccines, even though sublingual immunotherapy for allergies is already mainstream.

Emerging Technologies

The next generation of oral vaccines is trying to solve the problems that have limited the current ones: acid degradation, inconsistent gut uptake, and the risks of live virus reversion. Several approaches are in early development.

One uses food-grade bacteria as delivery vehicles. Recombinant strains of Lactococcus lactis, a bacterium used in cheese-making, have been engineered to express the SARS-CoV-2 spike protein. In a mouse study, oral immunization with these bacteria combined with a retinoic acid adjuvant produced measurable anti-spike antibodies, though the results did not reach statistical significance.²⁶ The concept is appealing because food-safe bacteria survive the gut naturally, but getting enough antigen expressed and delivered remains a challenge.

Another approach encapsulates antigens inside immune-stimulating particles. Glucan particles, derived from yeast cell walls, have been used to package both the SARS-CoV-2 spike protein and an immune-boosting compound called CL097 (a TLR7/8 agonist). In animal studies, this formulation triggered both blood IgG and mucosal secretory IgA, along with cellular immune responses.²⁴

Perhaps the most ambitious frontier is oral mRNA delivery. The mRNA vaccines used against COVID-19 transformed vaccinology, but they require injection and cold storage. Oral mRNA faces the brutality of the digestive system. Researchers have engineered capsule-based devices called RNACap that protect liquid mRNA nanoparticles until they reach the intestine, where the nanoparticles can transfect intestinal cells.²⁷ Another group has used bovine milk-derived exosomes, tiny vesicles naturally present in cow’s milk, to carry mRNA encoding the SARS-CoV-2 receptor binding domain. In mice, oral delivery of this formulation stimulated neutralizing antibodies.²⁸ The milk exosome approach is particularly interesting because it leverages a natural packaging system that is already designed to survive digestion.

Edible vaccines grown in transgenic plants have been explored for decades. The idea is to engineer a food crop to produce a vaccine antigen in its tissues, so that eating the plant amounts to receiving a dose. Expression levels of the antigen in plant tissues have generally been low, but in some feeding studies the quantities produced were enough to induce immune responses in animals.²⁹ The regulatory hurdles for edible vaccines are enormous, since the product is simultaneously a food, a drug, and a genetically modified organism, but the long-term vision of growing vaccines in banana plants or rice paddies has not gone away.

When an Oral Vaccine Makes Sense and When It Does Not

Oral vaccines shine when the disease infects through a mucosal surface and the goal is to build a first line of defense right where the pathogen enters. They are also the practical choice when millions of doses need to be delivered quickly in settings where trained health workers, needles, and refrigeration are scarce. For polio eradication, the logistical simplicity of two drops on the tongue made mass campaigns feasible across entire continents.

They are less suitable when precise dosing matters, when the antigen is fragile and difficult to protect from digestion, or when the target population has a high prevalence of gut inflammation or maternal antibody interference. Injected vaccines bypass all of those gut-related obstacles. For diseases where gut mucosal immunity is not critical to protection, like measles or hepatitis B, injection remains the more reliable route. The future likely holds not a replacement of needles by pills, but a more strategic pairing: oral or mucosal vaccines layered on top of injectable ones where the combination offers better protection than either alone, as has already been explored with mixed polio vaccine schedules combining OPV and IPV.